Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/31/12 | 10-Q/A | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
6 |
| 12/28/12 | 10-Q/A | Quarterly report pursuant to Section 13 or 15(d) |
|
|
36 |
| 12/28/12 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
|
64 |
| 12/21/12 | 8-K | Current report filing |
|
7 | |
| 12/21/12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
41 | |
| 12/19/12 | 8-K | Current report filing |
|
5 | |
| 12/19/12 | 10-Q/A | Quarterly report pursuant to Section 13 or 15(d) |
|
48 | |
| 12/17/12 | 8-K | Current report filing |
|
5 | |
| 12/17/12 | 10-Q/A | Quarterly report pursuant to Section 13 or 15(d) |
|
40 | |
| 12/04/12 | 8-K | Current report filing |
|
6 |
